|
First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC). |
|
|
Honoraria - AstraZeneca; Janssen; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; BioClin Therapeutics; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine; Foundation Medicine |
|
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis; Genocea Biosciences |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Honoraria - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Simone Luca Antonio Scuderi |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Ferring; Janssen-Cilag; MDxHealth; OPKO Health |
Research Funding - Sandoz-Novartis |
|
|
No Relationships to Disclose |